-
Taletrectinib Approved for Locally Advanced and Metastatic NSCLC with ROS1 Rearrangements
On June 11, 2025, the US Food and Drug Administration (FDA) announced the approval of taletrectinib (Ibtrozi™) to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)...
IN THE SPOTLIGHT
-
Surviving LMD: Michelle Never Settled for “No”
Michelle knew what was wrong. She knew the headaches, regular vomiting, ear popping, and “whooshing” sounds in her head were all signs of leptomeningeal disease (LMD). The issue... -
New Treatment Approved for NSCLC with High Level of c-Met Protein
On May 14, 2025, the US Food and Drug Administration (FDA) announced the approval of telisotuzumab vedotin-tllv (EMRELIS™) to treat patients with locally advanced or metastatic non... -
The Promise of PROTACs for Treating RET+ Lung Cancer
RET proteins are a type of receptor tyrosine kinase—an important group of signaling molecules in healthy cells. When RET proteins are turned “on” and “off” in healthy cells, they... -
Watch HOPE Summit Videos
HOPE Summit 2025 was filled with messages of hope, meeting new and hugging old friends, and of course the inspirational and informative sessions that help people live well with... -
What Are Antibody-Drug Conjugates and How Do They Treat Lung Cancer?
Historically, approaches to treating lung cancer included surgery, radiation, and chemotherapy. The past decade ushered in a new era of treatments with targeted therapy and... -
Integrative Oncology and Lung Cancer: Adding Complementary Therapy
What Is Integrative Oncology? Integrative oncology is the use of complementary therapies alongside conventional lung cancer treatments like chemotherapy, targeted therapy, surgery... -
What Should Patients Know About Lung Cancer Surgery?
Surgery is a treatment option for early-stage lung cancer that involves removing all or part of a lung to treat a cancerous tumor. It is primarily an option for people with non... -
Protein Degraders in Cancer Treatment: What They Are and How They Work
Join us for an engaging Facebook Live discussion on the role of RET gene alterations (fusions and mutations) in cancers such as lung and thyroid cancer. While current therapies... -
Rare Mutations (RET, ROS1, MET, BRAF) Virtual Meetup
Rare Mutation (RET, ROS1, MET, BRAF) patients/survivors - Join us the 1st Wednesday of every month to c onnect with others who share common experiences and build your community...
Surviving LMD: Michelle Never Settled for “No”
Surviving LMD: Michelle Never Settled for “No”
Michelle knew what was wrong. She knew the headaches, regular vomiting, ear popping, and “whooshing” sounds in her head were all signs of leptomeningeal disease (LMD). The issue, however, is that LMD is so rare—only diagnosed in 5% of people with cancer—she had to advocate for the testing to prove it.“I called my clinic and said I needed a brain MRI because I think I have LMD. They didn’t want to schedule one, so I said, tell my doctor I’m demanding a brain MRI. I can tell him directly if I…
Laughs for Lungs: Rasheed Marshall Combines Comedy With Cancer
Laughs for Lungs: Rasheed Marshall Combines Comedy With Cancer
Rasheed Marshall understands the secondhand effects of cancer well. First his mom, Joycelyn, was diagnosed with breast cancer in 1995. It came back in 2015 and eventually metastasized (spread) to her lungs. Soon after, his brother-in-law Romain was diagnosed with brain cancer. They both passed away the same week. “It was tough for the entire family when we learned mom’s cancer came back. She didn’t want to go through treatment again—which is why she didn’t tell us about it right away—so…
Let Your Voice Be Heard!
Let Your Voice Be Heard!
We are collecting stories from patients, caregivers, friends, and family members! Tell us how lung cancer has affected your life. Email your story to us at support@lungevity.org. Thanks!
RET, MET, and EGFR: An unusual tale of three oncogenes in lung cancer
RET, MET, and EGFR: An unusual tale of three oncogenes in lung cancer
LUNGevity's Upal Basu Roy, PhD, MPH, Executive Director, Research, discusses innovative research into RET+ NSCLC with patient advocates and the scientist conducting the studies. Panelists include Omaima Salous (diagnosed with RET+ NSCLC and co-founder of The Hamoui Foundation), Dr. Hilary Hammell (diagnosed with RET+ NSCLC and co-chair of RETpositive), and Dr. Tejas Patil (Assistant Professor, University of Colorado). The discussion focuses on Dr. Patil’s RET+ NSCLC research project…